# **Mebicar**®

## International Non-Proprietary Name (INN): Mebicar

Dosage Form: pills (300 mg or 500 mg)

**Structure:** 1 pill contains:

Active ingredient: mebicar 300mg or 500 mg.

Excipients: povidone (high-molecular polyvinylpyrrolidone),

calcium stearate.

<u>Description:</u> Flat cylindrical pills of white color with a facet and a break line.

**Pharmacological classification:** tranquilizer (anxiolytic)

ATC code: N05BX.

<u>Pharmacological action:</u> anxiolytic, stress-protective, nootropic, cardioprotective

# **Pharmacodynamics:**

Mebicar is an anxiolytic, stress-protective, nootropic medication. It enhances oxygen supply in myocard tissues; improves electrolyte balance disorders of blood, improves the content of potassium ions in plasma, in erythrocytes and in myocardium cells; potentiates protein synthesis and an increase of the cell energy potential.

Mebicar normalizes sleeping if disturbed without having direct hypnotic action. It does not have a cholinolytic and myorelaxing effect. It does not disturb motor performance. It mitigates or relieves nicotine withdrawal symptoms.

#### **Pharmacokinetics:**

Absorption: 78-80% of the dosage is absorbed into the blood.

The maximum concentration of the active ingredient in blood is reached in 0.5 hours after taking the drug.

*Distribution:* Mebicar is freely distributed throughout the organism and it freely comes through the cell membranes.

*Excretion:* Fully excretes from the body in urine within 24 hours.

#### Intended uses:

- neurotic disorders (irritability, emotional instability, anxiety, anxio-depressive, phobic, panic disorders) which come as a result of exhausting psychoemotional, neuropsychic and physical activities:
- (as part of complex therapy) treating patients with cardialgia, coronary heart disease and for rehabilitation after myocardial infarction:
- reduction of tobacco addiction;
- treatment of neurosis-like states of patients who suffer from alcohol dependence, reduction of the morbid addiction to the alcohol and to psychoactive substances;
- improvement of tolerability to neuroleptics and tranquilizers.

#### **Contraindications:**

Hypersensitivity to the components of the drug, age below 18 years, pregnancy and lactation.

### **Dosage and administration:**

Ingest by mouth without regard to timing of food: 300-900 mg 2-3 times a day.

The maximum single dosage is 3 g; the maximum daily dosage is 10 g. The length of the treatment varies from several days to 2-3 months. Depending on the patient's condition, in case of mental disorders - up to 6 months.

With irritability, fear, emotional lability, anxiety it is recommended to administer 300-600 mg 3 times a day.

With vegetative and mental disorders (including anxiety, fear, loss of attention and memory, asthenia, not associated with

coronary artery disease) it is recommended to take 600-900 mg of the drug 3 times a day.

To reduce the craving for alcohol and nicotine, as well as for nicotine and alcohol abstinence, it is recommended to take 600-900 mg of the drug 3 times a day. Duration of the treatment course lasts up to 1.5 months.

Patients with severe psychopathic disorders caused by organic brain changes and with the development of intolerance to neuroleptic drugs take 900-1800 mg of the drug three times a day.

### Side effects:

Allergic reactions (skin rashes, itching), decrease of arterial pressure, hyperthermia, dyspepsia.

Decrease of arterial pressure or body temperature do not require cessation of treatment. Blood pressure and body temperature return to normal on their own.

#### Overdose:

The toxicity of Mebicar is very low. Severe overdose is likely to increase the severity of side effects. In such cases it is necessary to conduct conventional treatment for detoxification.

#### **Interaction with other drugs:**

Mebicar potentiates the effect of hypnotic and narcotic drugs.

#### **Pregnancy and lactation:**

Due to the lack of clinical research data Mebicar is not recommended during pregnancy and lactation. If you need to take the drug during lactation, breastfeeding should be discontinued.

# <u>Influence on the ability to drive vehicles and operate</u> <u>mechanisms:</u>

Special caution should be taken during the treatment period when driving vehicles and operating mechanisms.

Terms of release from pharmacy: on prescription

<u>Storage conditions:</u> store in dry places at room temperature. Keep out of reach of children.

**Shelf life:** 4 years. Do not use beyond the expiration date.

**Country of manufacture:** Russia